Evidence map›Paper›PMID 26622051›Full record

Trial reportDiabetes care2016

Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.

Sandeep Dhindsa, Husam Ghanim, Manav Batra, Nitesh D Kuhadiya, Sanaa Abuaysheh, Sartaj Sandhu, Kelly Green, Antoine Makdissi, Jeanne Hejna, Ajay Chaudhuri and 2 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 6 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 6 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sandeep DhindsaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY Division of Endocrinology, Diabetes and Metabolism, Texas Tech University Health Sciences Center, Odessa, TX.
Husam GhanimDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Manav BatraDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Nitesh D KuhadiyaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Sanaa AbuayshehDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Sartaj SandhuDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Kelly GreenDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Antoine MakdissiDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Jeanne HejnaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Ajay ChaudhuriDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY.
Mark PunyanityaImage Reading Center, Inc., New York, NY.
Paresh DandonaDivision of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, Buffalo, NY pdandona@kaleidahealth.org.
University at Buffalo, State University of New York · USTexas Tech University · US

Funding

Testosterone effects on insulin sensitivity & inflammation in T2DM and obesityR01DK075877 · NIDDK · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DANDONA, PARESH · 2009 to 2012
$2.3M
NIDDK NIH HHS R01 DK075877NIDDK NIH HHS R01-DK-075877
6 · The paper itself

Abstract

objectiveOne-third of men with type 2 diabetes have hypogonadotropic hypogonadism (HH). We conducted a randomized placebo-controlled trial to evaluate the effect of testosterone replacement on insulin resistance in men with type 2 diabetes and HH. RESEARCH DESIGN AND

methodsA total of 94 men with type 2 diabetes were recruited into the study; 50 men were eugonadal, while 44 men had HH. Insulin sensitivity was calculated from the glucose infusion rate (GIR) during hyperinsulinemic-euglycemic clamp. Lean body mass and fat mass were measured by DEXA and MRI. Subcutaneous fat samples were taken to assess insulin signaling genes. Men with HH were randomized to receive intramuscular testosterone (250 mg) or placebo (1 mL saline) every 2 weeks for 24 weeks.

resultsMen with HH had higher subcutaneous and visceral fat mass than eugonadal men. GIR was 36% lower in men with HH. GIR increased by 32% after 24 weeks of testosterone therapy but did not change after placebo (P = 0.03 for comparison). There was a decrease in subcutaneous fat mass (-3.3 kg) and increase in lean mass (3.4 kg) after testosterone treatment (P < 0.01) compared with placebo. Visceral and hepatic fat did not change. The expression of insulin signaling genes (IR-β, IRS-1, AKT-2, and GLUT4) in adipose tissue was significantly lower in men with HH and was upregulated after testosterone treatment. Testosterone treatment also caused a significant fall in circulating concentrations of free fatty acids, C-reactive protein, interleukin-1β, tumor necrosis factor-α, and leptin (P < 0.05 for all).

conclusionsTestosterone treatment in men with type 2 diabetes and HH increases insulin sensitivity, increases lean mass, and decreases subcutaneous fat.

Indexed as

Hormone Replacement TherapyInsulin ResistanceAdultBody CompositionC-Reactive ProteinDiabetes Mellitus, Type 2Fatty Acids, NonesterifiedHumansHypogonadismInflammationInsulinInterleukin-1betaIntra-Abdominal FatLeptinMaleMiddle AgedC-Reactive ProteinFatty Acids, NonesterifiedIL1B protein, humanInsulinInterleukin-1betaLeptinTestosteroneTumor Necrosis Factor-alpha

Identifiers

PMID26622051
PMCPMC4686848
OpenAlexW2208778639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.